Bradley Foster & Sargent Inc. CT Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

Posted by Brenda Bartman on Jul 26th, 2026

Bradley Foster & Sargent Inc. CT decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 13.5% during the first quarter, Holdings Channel reports. The firm owned 73,840 shares of the medical research company’s stock after selling 11,532 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in IQVIA were worth $12,593,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA during the 4th quarter valued at $25,000. Financial Freedom LLC bought a new position in shares of IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of IQVIA in the 1st quarter worth $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at $27,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE IQV opened at $208.22 on Friday. The business’s fifty day moving average is $188.23 and its 200 day moving average is $187.38. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $34.75 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the business posted $2.70 earnings per share. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IQV shares. Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Mizuho upped their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Finally, Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $225.71.

Check Out Our Latest Report on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.